The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hip OA

Major Grant Funding for Collaborative RA Projects

  |  

In the last three years, the ACR REF has raised more than $26 million toward the $30-million goal for the Within Our Reach: Finding a Cure for Rheumatoid Arthritis (RA) campaign. Even in the worst economy this country has seen since the Great Depression, in fiscal year 2009, contributions to the Within Our Reach campaign exceeded $6.1 million. For the first quarter of fiscal year 2010, more than $1.1 million has already been received.

Health Professional Preceptee Joins the World of Rheumatology

  |  

As a graduate student and biostatistician in the Musculoskeletal Research Center at the Institute for Aging Research of Hebrew SeniorLife, Boston, Alyssa B. Dufour was unsure where to focus her research interests.

Is Improving Your Career One of Your Resolutions?

Cynthia M. Piccolo  |  

Another New Year’s has just passed, and if you’ve opted for one of the typical resolutions, you’ve decided to lose weight, exercise more, or quit a nasty habit like smoking. If you’re one to make resolutions, have you considered adding a career-related resolution to your self-improvement goals for the new year? Most of us spend a significant portion of our lives at work, so it makes sense.

Without You, ACR REF Wouldn’t Be Here

  |  

In 1998, the ACR Research and Education Foundation (REF) funded a total of $500,000 in grants. This year, the REF funded more than $4.6 million in grants through its core portfolio, which is an increase of over $4 million in funding capabilities in just 10 years. The REF also achieved the distinction of becoming the second largest funding source—just behind the National Institutes of Health (NIH)—of rheumatology research and training programs in the United States and was recently awarded the prestigious four-star rating from Charity Navigator. These achievements could not have been realized without the generous financial support of REF donors.

Letters to the Editor: In Memoriam

The Rheumatologist  |  

One more prescribing rule [See “Rheuminations,” September 2009, p. 6], honored mainly in the breach, in our overspending climate: don’t prescribe an expensive brand when generics are as good or better, especially Nexium (which I have never prescribed) versus omeprazole, Lipitor versus simvastatin (which now costs the VA three cents a pill), and—for rheumatologists who are writing 80% Uloric—allopurinol except for the 10% who might need Uloric.